Immune therapy booster for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug that may make immunotherapy more effective for people with triple-negative breast cancer that has not yet been treated. The drug, isunakinra, targets inflammation that can help tumors hide from the immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18
- You have been newly diagnosed with triple-negative breast cancer that has not yet been treated
- Your cancer is locally advanced, meaning it is in the breast or nearby lymph nodes
- You are willing to provide at least two biopsy samples from your tumor
- You are in good overall health (able to do light activity) and your organs are functioning well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
This trial tests an experimental drug called ivarmacitinib to see if it can help your body's immune system fight triple-negative breast cancer when immunotherapy alone has stopped working. It is a pill you take by mouth, and this study is in phase 2, meaning it's being tested for effectiveness in a larger group.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.